AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Phase 3AmpligenPositive

AI Analysis

Summary

AIM ImmunoTech signed an agreement with PPD (Thermo Fisher Scientific) to design a Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer treatment. The announcement represents an advancement in the drug's development pathway but is a planning agreement rather than trial initiation.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Agreement signed for planning of proposed Phase 3 clinical trial design

Importance:6/10

Sentiment:

0.50

Phase 3 trialpancreatic cancerAmpligenclinical developmentpartnership

Related Companies

$AIM

Read the original article

Published by GlobeNewswire Clinical Studies on March 2, 2026 2:00 PM

Read Original